TWO · 6917.TWO
Andros Pharmaceuticals Co.,Ltd
NT$32.25-NT$0.90 (-2.71%)
Andros Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 29.82% below the high.
Loading market information…
TWO · 4117.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 06:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
General Biologicals Corporation’s quoted price sits in the lower half of its reported 52-week range, 64.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow General Biologicals Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
General Biologicals Corporation (GBC) is a company dedicated to the research, development, production, and global commercialization of in-vitro diagnostic (IVD) solutions, operating extensively both within Taiwan and internationally. The company's core diagnostic offerings include advanced ELISA and chemiluminescence immunoassays, molecular and cellular diagnostic platforms, and rapid point-of-care testing (POCT) systems. Its diverse portfolio further encompasses COVID-19 related solutions, digital pathology, and contract development manufacturing organization (CDMO) services. Additionally, GBC provides essential blood screening services for detecting hepatitis and HIV, alongside crucial biomaterials such as antibody preparations and human plasma. Venturing beyond diagnostics, the company also markets a line of oral care products under its proprietary 'oh care' brand. These diagnostic systems are primarily utilized by clinics and laboratories. Founded in 1973, General Biologicals Corporation is headquartered in Hsinchu City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$32.25-NT$0.90 (-2.71%)
Andros Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 29.82% below the high.
NT$46.00NT$0.00 (0.0%)
S&S Healthcare Holding Ltd.’s quoted price sits in the upper half of its reported 52-week range, 12.38% below the high.
NT$30.15NT$0.00 (0.0%)
Concord Medical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.75% below the high.
NT$15.85-NT$0.20 (-1.25%)
Radiant Innovation Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.7% below the high.
NT$16.60-NT$0.30 (-1.78%)
Healthconn Corp.’s quoted price sits in the lower half of its reported 52-week range, 31.97% below the high.
NT$18.65NT$0.00 (0.0%)
TFBS Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.03% below the high.
NT$6.35-NT$0.34 (-5.08%)
PlexBio Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 59.81% below the high.
NT$16.90+NT$0.40 (+2.42%)
SynCore Biotechnology Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 41.32% below the high.
